| Accession |
PRJCA029840 |
| Title |
A PHASE 1, OPEN LABEL STUDY EVALUATING THE PHARMACOKINETICS, SAFETY, AND TOLERABILITY OF ARV-471 (PF-07850327) AS A SINGLE AGENT IN CHINESE PARTICIPANTS WITH ER+/HER2- ADVANCED BREAST CANCER |
| Relevance |
Medical |
| Data types |
Variation
|
| Organisms |
Homo sapiens
|
| Description |
To determine single-dose and multiple-dose PK profiles of ARV-471 and ARV-473 (an epimer of ARV-471) in Chinese participants with ER+/HER2- advanced breast cancer |
| Sample scope |
Monoisolate |
| Release date |
2024-10-15 |
| Grants |
| Agency |
program |
Grant ID |
Grant title |
| No funding support
|
|
|
|
|
|
| Submitter |
Rong
Cao (rong.cao@pfizer.com)
|
| Organization |
Pfizer (China) Research and Development Co. Ltd. |
| Submission date |
2024-09-04 |
